Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Retrospective Study of Adult Patients With Inborn Errors of Metabolism in Switzerland

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03534752
Recruitment Status : Recruiting
First Posted : May 23, 2018
Last Update Posted : April 22, 2019
Sponsor:
Information provided by (Responsible Party):
Christel Tran, University of Lausanne

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a retrospective study aimed at establishing a database of the current health of adult patients with IEM in the French-speaking part of Switzerland. .

Condition or disease
Inborn Errors of Metabolism

Detailed Description:

Background Inborn errors of metabolism (IEMs) are a group of rare disorders caused by genetic mutations that affect enzymes of intermediary metabolism. Because adult with IEMs has become an emerging and challenging group in Switzerland, this study is intended to assess the actual situation of adult patients with IEM in the French-speaking part of Switzerland, namely their age, their sex, their diagnosis, age at disease onset and their clinical outcome including complications of the disease.

All adult patients with a biochemical and/or genetic diagnosis of IEM followed at the adult metabolic clinic from the Lausanne University Hospital and Geneva University Hospital between 01.10.2013 to 31.12.2017 will be included in the study. In addition, investigators will also include the patients referred to the clinic for suspicion of IEM and determinate if the investigation confirmed an IEM disease. Electronic and paper patient charts will be reviewed for clinical features, biochemical investigations, molecular genetic testing, diagnostic imaging, treatment and long-term outcome. All data will be entered in an Excel database.


Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Clinical Characteristics of Adult Patients With Inborn Errors of Metabolism in French-speaking Switzerland
Actual Study Start Date : April 1, 2018
Actual Primary Completion Date : April 1, 2019
Estimated Study Completion Date : April 1, 2020
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Specific diagnosis of IEM listed by their frequency [ Time Frame: First visit ]
    Clinical outcome

  2. Age at diagnosis (years/months) [ Time Frame: First visit ]
    Clinical outcome

  3. Medical complications [ Time Frame: 4 years ]
    Clinical outcome including acute liver failure, nephropathy, metabolic acidosis, ophthalmologic anomalies, epilepsy, encephalopathy, myopathy, neuropathy, diabetes

  4. Specific treatment for Inborn Errors of Metabolism [ Time Frame: 4 years ]
    Treatment specific to each diseases including ammonia scavenger, enzyme replacement therapy, carnitine, ubiquinone, vitamins, specific diet, dialysis, specific metabolic formula

  5. Number of hospital admission [ Time Frame: 4 years ]
    Clinical outcome

  6. Survival rate (%) [ Time Frame: 4 years ]
    Clinical Outcome

  7. Gender (Male/female) [ Time Frame: First visit ]
    Demography outcome


Secondary Outcome Measures :
  1. Abdominal Ultrasound results [ Time Frame: 4 years ]
    Radiological Imaging description of spleen and/or liver when available (size, echostructure)

  2. Magnetic resonance Imaging scan [ Time Frame: 4 years ]
    Radiological Imaging description of brain, abdomen and bone when available

  3. Bone density test [ Time Frame: 4 years ]
    Radiological Imaging description of bone including T-score when available

  4. Biological biomarkers of specific diseases (lysosomal storage disorders and galactosemia) [ Time Frame: 4 years ]
    Laboratory including blood concentration of chitotriosidase and Galactose-1-Phosphate

  5. Clinical chemistry [ Time Frame: 4 years ]
    Laboratory including blood concentration of sodium, potassium, liver function tests, creatinine, uric acid, urea, amino acids, acylcarnitine profile, methylmalonate, total homocysteine and urine concentration of organic acids

  6. Hematology tests [ Time Frame: 4 years ]
    Laboratory (blood count, international normalized ratio, prothrombin time)

  7. Enzyme activity in leucocytes and/or fibroblasts [ Time Frame: 4 years ]
    Enzyme activity of deficient enzyme when available for lysosomal storage diseases, mucopolysaccharidoses, cobalamin deficiency, diseases, classical homocystinuria

  8. Molecular analysis results of candidate gene for Inborn Errors of metabolism [ Time Frame: 4 years ]
    Laboratory including mutation results confirming the molecular origin of the disease when available


Other Outcome Measures:
  1. Educational level [ Time Frame: 4 years ]
    Demography outcome

  2. Profession [ Time Frame: 4 years ]
    Demography outcome


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatient clinic for Adult patients with Inborn Errors of Metabolism from the Lausanne University Hospital (Division of Genetic Medicine) and Geneva University Hospital (Division of Endocrinology, Diabetology, Hypertension and Nutrition of the HUG.
Criteria

Inclusion Criteria:

  • All IEM adult patients who were transitioned from the pediatric clinic to the adult metabolic clinic (the Centre for Molecular Disease in Lausanne and the Division of Endocrinology, Diabetology, Hypertension and Nutrition of the HUG) since its creation in 2013 and those who were referred to our clinic for suspicion of IEM and requiring further investigation.

Exclusion Criteria:

  • Age > 16 years . Any document attesting a refusal to participate will exclude the data entry of the concerned patient.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03534752


Contacts
Layout table for location contacts
Contact: Christel Tran, MD +41213143680 christel.tran@chuv.ch

Locations
Layout table for location information
Switzerland
Lausanne University Hospitals Recruiting
Lausanne, Vaud, Switzerland, 1011
Contact: F , MD         
Sponsors and Collaborators
University of Lausanne
Investigators
Layout table for investigator information
Principal Investigator: Christel Tran, MD Lausanne University Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Christel Tran, Principal Investigator, University of Lausanne
ClinicalTrials.gov Identifier: NCT03534752     History of Changes
Other Study ID Numbers: 2017-02328
First Posted: May 23, 2018    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Christel Tran, University of Lausanne:
Inborn errors of Metabolism
Adulthood
Clinical characteristics
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases